Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Mitomycin × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 9 Anus Neoplasms 6 Colorectal Neoplasms 5 Appendiceal Neoplasms 5 Peritoneal Neoplasms 4 Carcinoma, Transitional Cell 3 Stomach Neoplasms 2 Pseudomyxoma Peritonei 2 Ovarian Neoplasms 2 Uterine Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Pleural Neoplasms 1 Neoplasm Metastasis 1 Necrosis 1 Nasopharyngeal Carcinoma 1 Mediastinal Neoplasms 1 Lung Metastases 1 Locally Advanced Anal Canal Cancer 1 Liver Neoplasms 1 HIV Infections 1 Gastrointestinal Neoplasms 1 Epstein-Barr Virus Infections 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma in Situ 1

Interventions

Cyclophosphamide 38 Dexamethasone 31 venetoclax 28 fludarabine 27 pembrolizumab 20 pomalidomide 17 Rituximab 17 Gemcitabine 16 Lenalidomide 14 Cytarabine 14 carfilzomib 11 Nivolumab 11 fludarabine phosphate 10 Temozolomide 10 Etoposide 10 Calcium Dobesilate 10 Azacitidine 10 glofitamab 9 daratumumab 9 Injections 9 obinutuzumab 8 Cisplatin 8 ibrutinib 7 cemiplimab 7 Carboplatin 7 Capecitabine 7 Bevacizumab 7 zanubrutinib 6 selinexor 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06781879 2025-10-03

COBRA-NMIBC

Aarhus University Hospital

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡